Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 14, 2020 07:00 ET | Source: Arvinas Inc.

Arvinas Releases Interim Clinical Data Further Demonstrating the Powerful Potential of PROTAC® Protein Degraders ARV-471 and ARV-110

– ARV-471 demonstrates evidence of anti-tumor activity, and potential for best-in-class safety, and estrogen receptor (ER) degradation profile and robust efficacy signals in a heavily pretreated...
December 11, 2020 16:15 ET | Source: Arvinas Inc.

Arvinas to Host Webcast Presentation of New Clinical Data from ARV-471 and ARV-110 PROTAC® Protein Degrader Development Programs

– Event to be webcast live on Monday, December 14, 2020 at 8:00 a.m. ET – NEW HAVEN, Conn., Dec. 11, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology...
November 25, 2020 07:00 ET | Source: Arvinas Inc.

Arvinas to Participate in Upcoming Virtual Investor Conferences

NEW HAVEN, Conn., Nov. 25, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
November 05, 2020 07:00 ET | Source: Arvinas Inc.

Arvinas Reports Third Quarter 2020 Financial Results and Provides Corporate Update

– First patient dosed in Phase 2 dose expansion cohort of ARV-110 trial – – Dose escalation for Phase 1/2 clinical trials of ARV-110 and ARV-471 continues; program updates planned for December 2020 –...
October 14, 2020 07:00 ET | Source: Arvinas Inc.

Arvinas Announces Pipeline Programs Targeting Validated and Classically “Undruggable” Disease-Causing Proteins

NEW HAVEN, Conn., Oct. 14, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
October 06, 2020 17:17 ET | Source: Arvinas Inc.

Arvinas to Present at the 3rd Annual Targeted Protein Degradation Summit

NEW HAVEN, Conn., Oct. 06, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
September 04, 2020 07:00 ET | Source: Arvinas Inc.

Arvinas to Present at the Citi 15th Annual BioPharma Virtual Conference

NEW HAVEN, Conn., Sept. 04, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
August 07, 2020 07:00 ET | Source: Arvinas Inc.

Arvinas to Present at the 2020 Wedbush PacGrow Virtual Healthcare Conference

NEW HAVEN, Conn., Aug. 07, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
August 04, 2020 07:00 ET | Source: Arvinas Inc.

Arvinas Reports Second Quarter 2020 Financial Results and Provides Corporate Update

NEW HAVEN, Conn., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biopharmaceutical company creating a new class of drugs based on targeted protein degradation,...
June 29, 2020 16:30 ET | Source: Arvinas Inc.

Arvinas Appoints Wendy Dixon, Ph.D., to its Board of Directors

NEW HAVEN, Conn., June 29, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...